Press release
Deadline on May 17th coming up in Lawsuit for Investors in CytoDyn Inc. (OTC: CYDY) shares
A Deadline is coming up on May 17, 2021 in the lawsuit for certain investors in CytoDyn Inc. (OTC: CYDY).
Investors who purchased shares of CytoDyn Inc. (OTC: CYDY) have certain options and there are strict and short deadlines running. Deadline: May 17, 2021. OTC: CYDY stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Western District of Washington the plaintiff alleges on behalf of purchasers of CytoDyn Inc. (OTC: CYDY) common shares between March 27, 2020 and March 9, 2021, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 27, 2020 and March 9, 2021, the defendants made materially false and/or misleading statements, and failed to disclose that while CytoDyn's stock price was sufficiently pumped with the COVID-19 cure hype, long-term shareholders, including CEO Nader Z. Pourhassan and CFO Michael Mulholland, dumped millions of shares, that CytoDyn engaged in a wrongful scheme with its lender, Iliad Research and Trading L.P. ("Iliad"), and its principal John Fife ("Fife"), whereby Iliad and other Fife entities operated as an unregistered securities dealer for CytoDyn, and that Iliad obtained a convertible promissory note from CytoDyn and converted the note into newly issued shares of CytoDyn and sold those shares into the public market at a profit, in violation of the dealer registration requirements of the federal securities laws.
Those who purchased shares of CytoDyn Inc. (OTC: CYDY) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on May 17th coming up in Lawsuit for Investors in CytoDyn Inc. (OTC: CYDY) shares here
News-ID: 2285646 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for CytoDyn
Triple Negative Breast Cancer Treatment Market Size Report 2034 | AstraZeneca, G …
DelveInsight's "Triple Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of TNBC, historical and forecasted epidemiology, as well as the TNBC market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Discover Key Insights into the Triple Negative Breast Cancer Market with DelveInsight's In-Depth Report @ Triple Negative Breast Cancer Market Size- https://www.delveinsight.com/sample-request/triple-negative-breast-cancer-tnbc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
Vasculitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Vasculitis pipeline constitutes 25+ key companies continuously working towards developing 30+ Vasculitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Vasculitis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/vasculitis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Vasculitis Market.
The Vasculitis Pipeline report embraces in-depth commercial and clinical…
Non alcoholic Steatohepatitis Clinical Trials Market to Witness Huge Growth by 2 …
The latest study released on the Global Non alcoholic Steatohepatitis Clinical Trials Market by USD Analytics Market evaluates market size, trend, and forecast to 2032. The Non alcoholic Steatohepatitis Clinical Trials market study covers significant research data and proofs to be a handy resource document for managers, analysts, industry experts and other key people to have ready-to-access and self-analyzed study to help understand market trends, growth drivers, opportunities and upcoming…
Endomucin Market Overall Study Report 2024-2032 | CytoDyn, Iovance Biotherapeuti …
The Endomucin Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2024 and 2032. It's like a compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its future. This report becomes a strategic ally for companies, stakeholders, and industry players, offering a comprehensive…
Vasculitis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Compani …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Vasculitis pipeline constitutes 20+ key companies continuously working towards developing 30+ Vasculitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Vasculitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Vasculitis Market.
The Vasculitis Pipeline report embraces in-depth…
Investigation announced for Long-Term Investors in CytoDyn Inc. (OTC: CYDY)
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of CytoDyn Inc.
Investors who are current long term investors in CytoDyn Inc. (OTC: CYDY) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in OTC: CYDY stocks follows a lawsuit filed against CytoDyn Inc. over…
